Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials

JAMA: The Journal of the American Medical Association

Volumn 266, Issue 1, 1991, Pages 93-98

  Yusuf, Salim ^a   Wittes, Janet ^b   Probstfield, Jeffrey ^a   Tyroler, Herman A ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b New England Research Institute Inc ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; PRIORITY JOURNAL; RANDOMIZATION;

CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DATA INTERPRETATION, STATISTICAL; HUMAN; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLING STUDIES;

EID: 0025737883     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03470010097038     Document Type: Article

References (37)

1. Bernard C; Green HC, trans. An Introduction to the Study of Experimental Medicine. New York, NY: Dover Publications Inc; 1957.
2. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol. 1982;14:473-482.
3. Bulpitt CJ. Subgroup analysis. Lancet. 1988;2:31-34.
4. Simon R, Wittes R. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep. 1985;69:1-3.
5. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980;303:1038-1041.
6. Yusuf S, Held P, Teo KK, Toretsky ER. Selection of patients for randomized controlled trials: implications of wide or narrow eligibility criteria. Stat Med. 1990;9:73-86.
7. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, I: treatments following myocardial infarction. JAMA. 1988;260:2088-2093.
8. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259-2263.
9. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarcto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
10. ISIS-2 Collaborative Group. Randomized trial of IV streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
11. Wilcox RG, von der Lippe G, Olsson CG, et al. Trials of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530.
12. AIMS Trial Study Group. Effect of intravenous ASPAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1985;1:545-549.
13. Yusuf S. Sleight P, Held P, MacMahon S. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990;82:117-134.
14. Miller RG Jr. Simultaneous Statistical Inference. 2nd ed. New York, NY: Springer-Verlag NY Inc; 1985.
15. Davis CE, Leffingwell DP. Empirical Bayes estimates of subgroup effects in clinical trials. Controlled Clin Trials. 1990;11:37-42.
16. Nelder JA. Discussion on papers by Wynn, Bloomfield, O’Neill, and Wetherill. J Royal Stat Soc Series B. 1971;33:244-246.
17. Systolic Hypertension in the Elderly Cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. J Clin Epidemiol. 1989;41:1197-1208.
18. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD)—rationale, design, and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
19. Furberg CD, Hawkins CM, Lichstein E. Effect of propranolol in post infarction patients with mechanical or electrical complications. Circulation. 1984;69:761-765.
20. Barber JM, Boyle DM, Chaturvedi NC, et al. Practolol in acute myocardial infarction. Acta Med Scand. 1976;587(suppl):213-219.
21. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI): a randomized placebo-controlled international trial. Eur Heart J. 1985;6:199-226.
22. Andersen MP, Bechsgaard P, Frederiksen J, et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: preliminary results. Lancet. 1979;2:865-868.
23. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Betablockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
24. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet. 1981;2:823-827.
25. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of acute myocardial infarction: ISIS-1. Lancet. 1986;2:57-66.
26. Wilhelmsson C, Vedin JA, Wilhelmsen I, et al. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Lancet. 1974;92:1157-1160.
27. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, II: morbidity results. JAMA. 1983;250:2814-2819.
28. The Beta-Blocker Pooling Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988;9:8-16.
29. Multicenter International Study. Supplementary report: reduction in mortality after myocardial infarction with long-term beta-adrenoreceptor blockade. BMJ. 1977;2:419-421.
30. Taylor SH, Silke B, Ebutt A, et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982;307:1293-1301.
31. Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Communications Stat. 1982;35:207-219.
32. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
33. The Coronary Drug Project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA. 1972;219:990-1008.
34. Knoke JD, Hawkins DL. Estimating baseline values of the variable of intervention in a clinical trial. Cont Clin Trials. 1985;6:136-145.
35. Wittes J, Lakatos E, Probstfield J. Surrogate endpoints in clinical trials: cardiovascular disease. Stat Med. 1989;8:415-425.
36. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987;6:245-250.
37. Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med. 1988;319:1681-1692.